EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis

Santiago Ramón-García, Rubén González Del Río, María Pilar Arenaz-Callao, Helena I Boshoff, Joaquín Rullas, Sara Anca, Mónica Cacho Izquierdo, Esther Porras de Francisco, Esther Pérez Herrán, Angel Santos-Villarejo, Alfonso Mendoza-Losana, Santiago Ferrer-Bazaga und 3 weitere

Drug Resistance Updates · 2025

DOI: 10.1016/j.drup.2025.101213 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2025. Verfasst von Santiago Ramón-García und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Pediatrics, Radiology and Public Health, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain; Research & Develop…. Hauptthemen laut MEDLINE: Antitubercular Agents, beta-Lactams, Drug Repositioning, Mycobacterium tuberculosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Intramural NIH HHS, National Institute of Allergy and Infectious Diseases Division of Intramural Research, FP7 People: Marie-Curie Actions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis (TB) is historically the world's deadliest infectious disease. New TB drugs that can avoid pre-existing resistance are desperately needed. The β-lactams are the oldest and most widely used class of antibiotics to treat bacterial infections but, for a variety of reasons, they were largely ignored until recently as a potential treatment option for TB. Recently, a growing body of evidence indicates that later-generation carbapenems in the presence of β-lactamase inhibitors could play a role in TB treatment. However, most of these drugs can only be administered intravenously in the clinic. We performed a screening of β-lactams against intracellular Mycobacterium tuberculosis (Mtb) and identified sanfetrinem cilexetil as a promising oral β-lactam candidate. Preclinical in vitro and in vivo studies demonstrated that: (i) media composition impacts the activity of sanfetrinem against Mtb, being more potent in the presence of physiologically relevant cholesterol as the only carbon source, compared to the standard broth media; (ii) sanfetrinem shows broad spectrum activity against Mtb clinical isolates, including MDR/XDR strains; (iii) sanfetrinem is rapidly bactericidal in vitro against Mtb despite being poorly stable in the assay media; (iv) there are strong in vitro synergistic interactions with amoxicillin, ethambutol, rifampicin and rifapentine and, (v) sanfetrinem cilexetil is active in an in vivo model of infection. These data, together with robust pre-clinical and clinical studies of broad-spectrum carbapenem antibiotics carried out in the 1990s by GSK, identified sanfetrinem as having potential for treating TB and catalyzed a repurposing proof-of-concept Phase 2a clinical study (NCT05388448) in South Africa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular Agentsbeta-LactamsDrug RepositioningMycobacterium tuberculosisTuberculosisAnimalsHumansMiceAdministration, OralMicrobial Sensitivity TestsTuberculosis, Multidrug-Resistant

Stichwörter der Autor:innen

IntracellularRepurposingSanfetrinemTuberculosisβ-lactams

Substanzen

Antitubercular Agentsbeta-Lactams

Autor:innen und Institutionen

  • Department of Microbiology, Pediatrics, Radiology and Public Health, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain; Research & Development Agency of Aragón Foundation (Fundación ARAID), Zaragoza, Spain; D…
  • Global Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.
  • Research & Development Agency of Aragón Foundation (Fundación ARAID), Zaragoza, Spain; Global Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.
  • Tuberculosis Research Section, NIH, Bethesda, USA.
  • Department of Microbiology and Immunology, Life Sciences Centre, University of British Columbia, Vancouver, BC, Canada.
  • Global Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain. Electronic address: robert.h.bates@gsk.com.

Förderung

  • Intramural NIH HHS
  • National Institute of Allergy and Infectious Diseases Division of Intramural Research
  • FP7 People: Marie-Curie Actions
  • Horizon 2020
  • H2020 Marie Skłodowska-Curie Actions
  • Horizon 2020 Framework Programme
  • National Institute of Allergy and Infectious Diseases
  • Seventh Framework Programme

Zitieren

APA

Ramón-García, S., González Del Río, R., Arenaz-Callao, M. P., Boshoff, H. I., Rullas, J., Anca, S., Cacho Izquierdo, M., Porras de Francisco, E., Pérez Herrán, E., Santos-Villarejo, A., Mendoza-Losana, A., Ferrer-Bazaga, S., Thompson, C. J., Barros Aguirre, D., & Bates, R. H. (2025). Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2025.101213

Vancouver

Ramón-García S, González Del Río R, Arenaz-Callao MP, Boshoff HI, Rullas J, Anca S, et al. Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis. Drug Resistance Updates. 2025. doi:10.1016/j.drup.2025.101213

BibTeX
@article{RamnGarca2025,
  author = {Ramón-García, Santiago and González Del Río, Rubén and Arenaz-Callao, María Pilar and Boshoff, Helena I and Rullas, Joaquín and Anca, Sara and Cacho Izquierdo, Mónica and Porras de Francisco, Esther and Pérez Herrán, Esther and Santos-Villarejo, Angel and Mendoza-Losana, Alfonso and Ferrer-Bazaga, Santiago and Thompson, Charles J and Barros Aguirre, David and Bates, Robert H},
  title = {Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis},
  journal = {Drug Resistance Updates},
  year = {2025},
  doi = {10.1016/j.drup.2025.101213}
}
Kostenlos starten →